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proteotoxic stress and compromise cellular proliferation, it is intriguing how chRCC, a tumor with extensive chromosome
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tumors of both The Cancer Genome Atlas kidney chromophobe (KICH) (n = 64) and M-chRCC (n = 35) cohorts was
associated with worse survival. In summary, our study provides genomic insights into the metastatic progression of
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Introduction
Renal cell carcinoma (RCC) consists of  morphologically, molecularly, and clinically distinct subtypes, 
including clear cell RCC (ccRCC, ~75%), papillary RCC (pRCC, ~15%), chromophobe RCC (chRCC, 
~5%), unclassified RCC (uRCC, ~5%), and few extremely rare entities such as medullary RCC (mdRCC) 
and MiT-translocation RCC (tRCC) (<1% each) (1–9). ChRCC is relatively indolent despite its usual 
presentation as larger tumors (10), yet ~5%–10% of  patients eventually develop metastases (11, 12). Thus 
far, there are no genomic biomarkers that predict metastatic progression, and no standard of  care for 
metastatic chRCC (M-chRCC) (13–17).
Conventional cytogenetic studies have demonstrated classical loss of  a nonrandom set of  7 chromosomes, 
i.e., 1, 2, 6, 10, 13, 17, and 21, in most chRCC (termed chRCC-7set hereafter) (5, 18), resulting in lower overall 
ploidy compared with other human cancers (19, 20). Recent genomic analyses of  2 chRCC cohorts of  66 
and 49 cases using contemporary platforms, encompassing whole-genome sequencing (WGS), whole-exome 
Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 
13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%–10% metastatic incidence. 
Since extensive chromosomal losses can generate proteotoxic stress and compromise cellular 
proliferation, it is intriguing how chRCC, a tumor with extensive chromosome losses and a low 
number of somatic mutations, can develop lethal metastases. Genomic features distinguishing 
metastatic from nonmetastatic chRCC are unknown. An integrated approach, including whole-
genome sequencing (WGS), targeted ultradeep cancer gene sequencing, and chromosome analyses 
(FACETS, OncoScan, and FISH), was performed on 79 chRCC patients including 38 metastatic 
(M-chRCC) cases. We demonstrate that TP53 mutations (58%), PTEN mutations (24%), and 
imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in 
M-chRCC. Reconstruction of the subclonal composition of paired primary-metastatic chRCC tumors 
supports the role of TP53, PTEN, and ICD in metastatic evolution. Finally, the presence of these 3 
genomic features in primary tumors of both The Cancer Genome Atlas kidney chromophobe (KICH) 
(n = 64) and M-chRCC (n = 35) cohorts was associated with worse survival. In summary, our study 
provides genomic insights into the metastatic progression of chRCC and identifies TP53 mutations, 
PTEN mutations, and ICD as high-risk features.
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sequencing (WES), mitochondrial DNA sequencing, DNA copy number array, mRNA sequencing, micro 
RNA sequencing, and DNA methylation array, affirmed an extremely hypodiploid genome with prevalent loss 
of  the chRCC-7set chromosomes, demonstrated the low (~31) exonic somatic mutation rate, and identified 
TP53 (20%–32%) and PTEN (6%–9%) as the only 2 significantly mutated genes (5, 21). However, the clinical 
significance of  these mutations in chRCC has not been established.
Since extensive chromosomal losses can generate proteotoxic stress and compromise cellular 
proliferation (22), it is puzzling that chRCC could develop lethal metastases. To investigate the molecular 
underpinnings of  metastatic progression in chRCC, we performed integrated genomic analyses on 49 
tumor samples from 38 M-chRCC cases, and conducted ultradeep targeted cancer gene sequencing on 
tumors from 41 nonmetastatic chRCC cases, and evaluated the impact of  identified high-risk genomic 
features on the overall survival of  chRCC patients using 2 independent cohorts.
Results
Clinical information of  cases and sample cohorts is outlined. Forty-nine tumor samples derived from 38 M-chRCC 
patients, including 37 primary and 12 metastatic tumors were denoted M-chRCC (Supplemental Figure 1; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.92688DS1). 
The additional 41 primary tumors from patients with nonmetastatic disease at the last documented follow-
up were denoted as indeterminate (ID-chRCC) due to the heterogeneous clinical follow-up information and 
the unknown incidence of  late recurrence among these patients (Supplemental Figure 1). For the validation 
of  results observed from this 79-patient cohort, genomic and updated clinical data of  66 chRCC cases from 
the published Cancer Genome Atlas kidney chromophobe (TCGA-KICH) study (5) were analyzed, among 
which 12 developed metastasis (M-chRCC) and the remaining 54 nonmetastatic chRCC were also denoted 
as ID-chRCC. Detailed clinical data can be found in Supplemental Table 1.
WGS on 5 M-hRCC cases identifies recurrent genomic aberrations. To investigate potential genomic features 
that underlie chRCC metastasis, we performed WGS using DNA purified from available fresh-frozen 
specimens representing 5 M-chRCC cases (4 primary tumors, JHCHR3, 4, 6, and 7; and 1 metastatic 
tumor, JHCHR5) along with matched normal tissue or blood (Figure 1 and Supplemental Figures 2 and 3). 
Tumors were sequenced to a mean haploid depth coverage of  ~90×, while normal samples were sequenced 
to ~50×. Large-scale subclonal copy number changes in WGS samples were analyzed using the Battenberg 
algorithm, which also supports the detection of  subclonal copy number events (23). Subclonal analysis was 
performed using an n-dimensional Bayesian Dirichlet process to group clonal and subclonal mutations 
(24). The fraction of  tumor cells carrying each mutation was calculated from the mutant allele fraction, 
taking into account the tumor purity and local copy number state (23, 24).
A wide range of  genomic rearrangements (0–149, mean 61), insertions/deletions (148–776, mean 334), 
and nucleotide substitutions (908–6,578; mean 2,725) were identified (Figure 1 and Supplemental Figures 
2 and 3). Recurrent somatic events were mutations in TP53 and PTEN, and homozygous loss of  CDKN2A 
(Figure 1B). Surprisingly, only 1 tumor exhibited a diploid genome with typical chRCC-7set–chromosomes 
loss (JHCHR5), while all other tumors had ploidy estimates above 2 (2.49–3.55, mean 3.05) (Figure 1B). 
This observation is in stark contrast to the known prevalent ~7-chromosome loss in chRCC that results in a 
hypodiploid genome (5, 18). However, B allele frequency (BAF) and copy number analyses (25) suggested 
gains in chromosomes that resulted in polyploid genomes, yet grossly exhibited the classical pattern of  
chRCC-7set–chromosome loss (Figure 1 and Supplemental Figure 2). This could be due to either loss of  the 
chRCC-7set chromosomes followed by duplication of  the remaining genome (JHCHR3, 4, and 7) (Figure 
1B), or duplication of  multiple chromosomes excluding the chRCC-7set (JHCHR6) (Figure 1B). To our 
knowledge, this pattern of  imbalanced sequential losses and gains of  sets of  multiple chromosomes has not 
been observed in other cancer types (19, 26). Hence, we refer hereafter to this nonrandom duplication of  
3 or more chromosomes in chRCC as imbalanced chromosome duplication (ICD). Altogether, our WGS 
analysis of  5 M-chRCC cases revealed recurrent somatic genomic events including mutations in TP53 and 
PTEN, homozygous loss of CDKN2A, and ICD.
TP53 and PTEN mutations are enriched in the primary tumors of  M-chRCC patients. To further evaluate these 
potentially high-risk genomic features of chRCC, we assembled an additional cohort consisting of 74 formalin-
fixed paraffin-embedded (FFPE) primary tumors from 33 M-chRCC and 41 nonmetastatic ID-chRCC 
patients (Supplemental Figure 1). Clinical features of this exploratory cohort (n = 74) are summarized in 
Table 1. Primary tumors and matched normal tissues were analyzed by ultradeep next-generation sequencing 
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Figure 1. Whole-genome sequencing analysis of 5 metastatic chromophobe renal cell carcinoma (M-chRCC) cases in the exploratory cohort. (A) 
Diagrams summarize the somatic alterations identified by the whole-genome sequencing (WGS) analysis of primary tumors from patients JHCHR3, 
JHCHR4, and JHCHR6. The uppermost track depicts inter- and intrachromosomal rearrangements as arcs. The copy number (CN) track shows the number of 
paternal and maternal copies of each chromosome (blue and red bars, respectively). The other tracks show total CN log-ratio (logR) and B allele frequency 
(BAF). See supplemental method for additional details. (B) Clonality analysis of 5 M-chRCC cases based on WGS data. Patient identification numbers are 
listed along with corresponding purity and ploidy estimates for the tumors generated with the Battenberg algorithm. Each branch represents a subclone 
and is annotated with alterations that could be assigned to the corresponding subclone. The length is proportional to the number of substitutions 
assigned by Dirichlet process clustering (see supplemental methods and Supplemental Figure 3 for details).
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(NGS) of 341 or 410 cancer-relevant genes 
(Supplemental Table 2) using Memorial Sloan 
Kettering-Integrated Mutation Profiling of  
Actionable Cancer Targets (MSK-IMPACT) 
assays (27). TP53 mutations were detected in 19 
of 33 (58%) M-chRCC and in 10 of 41 (24%) 
nonmetastatic ID-chRCC, and PTEN mutations 
were in 8 of 33 (24%) M-chRCC and in 3 of  
41 (7%) nonmetastatic ID-chRCC (Figure 2A 
and Supplemental Table 3). Homozygous loss 
of CDKN2A was detected in 1 of 33 M-chRCC 
and in 0 of 41 nonmetastatic ID-chRCC 
(Supplemental Table 3). Mutation frequencies 
of TP53, PTEN, and homozygous CDKN2A loss 
within our 41 ID-chRCC patients (24%, 7%, 
and 0%) are comparable to reported frequencies 
within the 54 TCGA-KICH ID-chRCC patients 
(26%, 7%, and 0%) (Supplemental Figure 
4 and Supplemental Table 5) (5). TP53 and 
PTEN mutations appear to be more frequent 
in the primary tumors of M-chRCC than 
nonmetastatic ID-chRCC patients, implying 
their roles in metastatic progression of chRCC. Of note, more than 1 TP53 mutation was detected in the 
primary tumors of 6 M-chRCC and 3 ID-chRCC cases (Figure 2A), reminiscent of the convergent mutation 
evolution of 3p tumor suppressors and the resulting intratumor heterogeneity in ccRCC (28).
The role of  TP53 and/or PTEN mutations in metastatic evolution of  chRCC is further evaluated through sequencing 
paired primary-metastatic tumor samples. To this end, we analyzed the 11 available metastatic tumors from 
8 paired primary-metastasis cases (Figure 2B, Supplemental Figure 1, and Supplemental Table 4). TP53 
mutations were detected in 9 (82%) of  11 tumors from 7 (88%) of  8 patients, and PTEN mutations were 
in 5 (45%) of  11 tumors from 4 (50%) patients (Supplemental Table 4). In the corresponding 8 primary 
tumors, 5 (63%) had TP53 and 2 (25%) had PTEN mutations (Figure 2A). In summary, both TP53 and PTEN 
mutations were more frequent in the metastatic tumors compared with the matched primary tumors.
To examine the spatiotemporal sequence of  genomic events concerning metastatic progression, we 
were able to reconstruct the subclonal composition of  5 of  the 8 paired primary-metastasis cases that 
have high tumor purity in both primary and metastatic samples (Figure 2B, and Supplemental Table 4). In 
patient 1, the TP53 R273H mutation was detected in the most recent common ancestor (MRCA) clone and 
hence present in both primary and metastatic lymph node samples (29). Private somatic events, such as 
NTRK1 and PLCG2 mutations, were present in either primary or metastatic samples, indicating branched 
evolution (30, 31). In patients 2 and 3, TP53 mutation was absent in the primary tumor but present in 
the metastatic lymph nodes. In patient 4, the same TP53 N310Tfs mutation was present in primary and 
metastatic lymph node samples, whereas 5 different PTEN mutations were detected and distributed 
among samples, demonstrating convergent mutation evolution of  PTEN (28, 31, 32). In patient 5, both 
TP53 and PTEN mutations were detected in the dominant clone and hence present in both primary and 
metastatic liver samples. ICD was detected in the primary but not the liver-metastasis tumor of  patient 
5. Notably, deletion of  the chRCC-7set chromosomes was evident in all MRCAs of  these 5 phylogenies, 
further supporting the role of  multiple chromosome loss as a very early oncogenic driver event in the 
pathogenesis of  chRCC.
Cross-platform analysis validates ICD in chRCC. In addition to TP53 and PTEN mutations, our WGS 
also identified ICD as a recurrent somatic event in M-chRCC (Figure 1). To evaluate chromosomal 
events, we employed fraction and allele-specific copy number (ASCN) estimates from tumor sequencing 
(FACETS) (33), a novel statistical and computational pipeline for analyzing ASCNs from NGS data of  
tumor-normal sample pairs. To validate chromosome-level events beyond NGS platforms (WGS, WES, 
and MSK-IMPACT), an orthogonal approach on assessing genome-wide DNA copy number alterations 
and allelic imbalances was performed using the OncoScan FFPE Array (Affymetrix) in samples with 
Table 1. Clinical and histopathologic characteristics of chRCC patients included in the 
exploratory cohort
M-chRCC (n = 33) ID-chRCC (n = 41)A
Median Age (min, max) 55 (39, 82) 55 (29, 86)
Median Tumor Size (min, max)B 12 (2.5, 29) 7.3 (1.2, 21.5)
Gender 16 males (48.5%) 25 males (65.8%)
17 females (51.5%) 13 females (34.2%)
AJCC
I 1 (3%) 21 (55.3%)
II 6 (18.2%) 9 (23.7%)
III 14 (42.4%) 8 (21.1%)
IV 12 (36.4%) 0
Clinical information NA = 0 NA = 3
Histology NA = 0 NA = 0
Eosinophilic 4 (12.1%) 11 (28.9%)
Sarcomatoid features 7 (21.2%) 1 (2.6%)
AClinical information of the nonmetastatic ID-chRCC cohort demographic information was 
summarized based on 38 cases due to insufficient clinical information in 3 of the 41 cases. BMedian 
pathologic tumor size (cm). M-chRCC, metastatic chromophobe renal cell carcinoma; ID-chRCC, 
indeterminate chRCC; AJCC, American Joint Committee on Cancer; NA, not available.
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sufficient remaining DNA (34). Furthermore, fluorescence in situ hybridization (FISH) assays utilizing 
chromosome-specific probes were conducted in select samples with sufficient numbers of  available 
unstained slides to visualize chromosome gains or losses. Altogether, FACETS results were independently 
validated with OncoScan in 17 samples and with FISH analysis over selectively deleted or amplified 
chromosomal regions in 14 samples (Supplemental Table 1).
The overall estimates of  total copy number and BAF were comparable between OncoScan and FACETS 
(Figure 3). One unique feature of  FACETS is the integer copy number output, where the total copy number 
and the minor allele copy number were corrected for tumor purity, ploidy, and clonal heterogeneity (33). 
Indeed, the loss of  1 copy of  chromosome 2 detected by OncoScan and FACETS (Figure 3, A and B) in 
the tumor was visualized with FISH assays using a 2p23/ALK probe (orange), and the retention of  2 copies 
of  chromosomes 1q and 4 was confirmed using a 1q23/NTRK1 (red) and a chromosome 4 pericentromere 
(green) probe, respectively (Figure 3C). There was no ICD detected in this patient’s tumor (Figure 3, A–C).
In contrast, ICD was detected in another patient’s tumor (Figure 3, D–F). The total copy number 
plots from OncoScan (Figure 3D) and FACETS (Figure 3E) showed a diploid pattern, whereas the 
Figure 2. Genomic landscape and clonal evolution of chromophobe renal cell carcinoma (chRCC) in the exploratory cohort. (A) Oncoprint summarizes 
the genomic features detected in the primary tumors in the exploratory cohort (n = 74). Crossed boxes in the uppermost track represent samples of which 
corresponding metastases were also sequenced. The presence of sarcomatoid histology is denoted. Imbalanced chromosome duplication (ICD) status and 
the loss of heterozygosity (LOH) at chromosome 17p were determined by FACETS outputs. Genes with mutation frequency 5% or greater are listed on the 
left. Mutation frequencies of individual genes in metastatic chRCC and indeterminate (ID) chRCC cases are shown as bar plots on the right. Gene mutation 
types are color coded. (B) Five subclonal compositions reconstructed on paired primary-metastasis samples. Most recent common ancestor (MRCA) 
depicts the clone carrying shared somatic mutation and copy number events of individual tumors. Multiple subclones with cancer cell fraction (CCF) less 
than 50% could be depicted either nested in the same cell (e.g., patient 1) or in parallel in a disjointed set of cells (e.g., patient 4).
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corresponding BAF plots showed widespread loss of  heterozygosity (LOH). The chRCC-7set chromosomes 
(1, 2, 6, 10, 13, 17, and 21) exhibited the most conspicuous allelic imbalance, whereas a range of  allelic 
imbalance was observed in the other chromosomes (Figure 3, D and E). For example, the near-diploid 
copy number of  chromosome 4 with a wide-split BAF indicated extreme allelic imbalance and suggested 
a loss of  chromosome 4 followed by a duplication of  the remaining chromosome 4 in most cells, whereas 
the increased copy number plot on chromosome 14 with a moderate-split BAF suggested a gain of  1 copy 
of  chromosome 14 without a prior chromosomal loss (Figure 3, D and E). Indeed, FISH analysis (Figure 
3F) demonstrated the presence of  2 copies of  chromosome 4 (red signal, 4p16/FGFR3) and 3 copies of  
chromosome 14 (green signal, 14q32/IGH), which concurred with the integer copy number estimated by 
FACETS (Figure 3E).
The prevalence of  ICD in chRCC is evaluated in our chRCC and the TCGA-KICH cohorts. Our data 
demonstrated that the FACETS algorithm offers a reliable resource for analyzing ASCNs based on targeted 
NGS panel data. Accordingly, we performed FACETS on all of  our samples and the TCGA-KICH cohort 
to assess ICD. All FACETS results were manually inspected, and the samples were assigned as ICD (+) 
status if  3 or more chromosomes were duplicated. Samples with a tumor purity estimate less than 30% or 
large amount of  noise and artifacts were excluded and assigned a not available (NA) status (Figure 2A, 
Table 1, and Supplemental Figure 4). Within the exploratory cohort (n = 74), ICD was present in 9 (12%), 
Figure 3. Characterization and validation of imbalanced chromosome duplication (ICD) through multiplatform ploidy analysis of 2 metastatic 
chromophobe renal cell carcinoma primary tumors. (A–C) For patient JH-kich-059, OncoScan output of copy number and B allele frequency plots (A) and 
FACETS output (B) of total copy number (log-ratio), B allele frequency  (BAF) (log-odds-ratio), integer copy number (em), and chromosome cancer fraction 
plots show typical pattern of losses in chromosomes 1p, 2, 6, 13, 17, and 22 reflected by the total ploidy of 1.63. (C) Three-color FISH image confirms loss of 
1 copy of chromosome 2 (2p23/ALK probe) and the retention of 2 copies of chromosomes 1q and 4 using 1q23/NTRK1 and chromosome 4 pericentromere 
(green) probes. (D–F) For patient JH-kich-058, total copy number plots from OncoScan (D) and FACETS outputs (E) show a diploid pattern, whereas the 
corresponding BAF plots display widespread loss-of-heterozygosity (LOH), with the most conspicuous allelic imbalance in the chRCC-7set chromosomes 
(1, 2, 6, 10, 13, 17, and 21). Increased integer copy numbers (em) for total alleles in most chromosomes suggest initial loss followed by gain of at least 1 copy 
of chromosome (E). ICD is confirmed by ploidy estimation of 2.83. FACETS integer copy number estimates are confirmed by FISH analysis (F), e.g., by the 
presence of 2 copies of chromosome 4 (4p16/FGFR3 probe) and 3 copies of chromosome 14 (14q32/IGH probe).
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absent in 50, and NA in 15 primary 
kidney tumors (Figure 2A). Among 
the 59 primary tumors with evaluable 
ICD status, ICD was present in 6 (25%) 
of  24 M-chRCC and in 3 (9%) of  35 
nonmetastatic ID-chRCC cases. Within 
the TCGA-KICH cohort, there were 66 
primary kidney tumors, among which 
ICD was present in 13 (20%) and absent 
in 53 cases (Supplemental Figure 4). ICD 
was present in 7 (58%) of  12 M-chRCC 
and in 6 (11%) of  54 nonmetastatic 
ID-chRCC cases within the TCGA-
KICH cohort. Altogether, our results 
show a 2.6- to 5.3-fold increase in the 
incidence of  ICD in primary tumors of  
M-chRCC versus ID-chRCC patients, suggesting a role for ICD in the metastatic progression of  chRCC.
The presence of  TP53 mutations, PTEN mutations, or ICD in the primary tumors associates with inferior survival 
outcome in the TCGA-KICH cohort. To evaluate the impact of  TP53 and PTEN mutations and ICD on chRCC 
patient survival, we analyzed the TCGA-KICH cohort (n = 64) (Figure 4 and Supplemental Table 5). 
Of  note, 2 of  the originally reported 66 cases (5) were excluded from survival analysis due to insufficient 
clinical information (Supplemental Figure 4 and Supplemental Tables 1 and 5). When stratified based on 
the TP53 mutation status, overall survival (OS) favored TP53 wild-type over TP53 mutant chRCC cases (P 
= 0.017), and 5-year OS of TP53 wild-type versus mutant chRCC was 94% (95% CI, 87%–100%) versus 
67% (48%–93%) (Figure 4A and Supplemental Table 5). When stratified based on PTEN mutation status, 
OS favored wild-type over mutant cases (P = 0.034), and 5-year OS of PTEN wild-type versus mutant was 
89% (81%–99%) versus 57% (30%–100%) (Figure 4B and Supplemental Table 5). When stratified based 
on ICD, OS favored ICD (–) over (+) cases (P = 0.012), and 5-year OS of  ICD (–) versus (+) was 91% 
(83%–100%) versus 55% (30%–100%) (Figure 4C and Supplemental Table 5). When all 3 high-risk features 
were combined, OS favored cases without any of  these high-risk features over those with any, but does not 
reach statistical significance (P = 0.059), and 5-year OS of  patients with no versus any feature was 97% 
(90%–100%) versus 74% (58%–93%) (Figure 4D and Supplemental Table 5). These data support the role 
of  these 3 genomic features in the clinical outcomes of  chRCC. Notably, although histology reports on the 
sarcomatoid status were missing in 40 of  the 64 TCGA-KICH patients (Figure 4 and Supplemental Table 
1), all 3 confirmed sarcomatoid cases have ICD, which is consistent with the reported high incidence of  
chromosomal gains in sarcomatoid chRCC tumors (35).
The presence of  TP53 mutations, PTEN mutations, or ICD in the primary tumors associates with inferior 
survival in M-chRCC patients. We next evaluated the association between TP53 mutations, PTEN mutations, 
or ICD and survival outcome in our M-chRCC cases cohort (n = 35) (Figure 5 and Supplemental Tables 
1 and 6). When stratified based on the TP53 mutation status, the OS favored TP53 wild-type over TP53 
mutant, but this association did not reach statistical significance (P = 0.099) (Figure 5A and Supplemental 
Table 6). When stratified based on PTEN, OS was similar between wild-type and mutant cases (P = 
Figure 4. The influence of mutations in 
TP53 or PTEN and ICD status on patient 
survival in the TCGA-KICH cohort. 
(A–D) Overall survival was evaluated in 64 
patients (TCGA-KICH cohort) based on TP53 
(A) and PTEN (B) mutational status and 
the imbalanced chromosome duplication 
(ICD) status (C), but also on the presence or 
absence of the 3 variables (D). Kaplan-Meier 
method and the log-rank test were used 
to compare the overall survival between 
groups. Cox regression estimated the 
hazard ratios (HRs).
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0.955) (Figure 5B and Supplemental Table 6). When stratified based on ICD, OS favored ICD (–) over 
(+) cases (P = 0.003) (Figure 5C and Supplemental Table 6), and when stratified based on sarcomatoid 
status, OS favored sarcomatoid histology (–) over (+) cases (P = 0.043) (Figure 5D and Supplemental 
Table 6). Notably, cases with any of  the 3 high-risk genomic features include all sarcomatoid cases 
(Figure 2A), and OS favored cases without any of  these high-risk features over those with any (P = 0.013) 
(Figure 5E and Supplemental Table 6).
Transcriptomic analysis of  the TCGA-KICH cohort identifies expression signature associated with the ICD status. 
To explore the potential molecular feature associated with ICD, we analyzed gene expression data from 
RNA sequencing by comparing ICD (+) to ICD (–) chRCC within the TCGA-KICH cohort. We identified 
976 differentially expressed genes (P < 0.01, t test; 451 up, 525 down) that were associated with a number 
of pathways (Figure 6A and Supplemental Table 7). For example, genes involved in cell proliferation were 
higher in ICD (+) chRCC, whereas those involved in mitochondrial function, located at chromosome 19q13 
locus, and targeted by TP53 were lower (Figure 6A). When evaluating the association between transcript levels 
and DNA methylation at corresponding CpG islands, coordinated changes were detected in chromosome 
19q13 genes (Figure 6B and Supplemental Table 7). Notably, the downregulation of 19q23 genes was shown 
to associate with SETD2 mutations in clear or papillary kidney cancers (20), whereas SETD2 mutation was not 
detected in chRCC (Supplemental Table 3) (5, 20).
Figure 5. The association 
between the presence of TP53 
mutations, PTEN mutations, 
or ICD in the primary tumors 
and the survival outcome 
in M-chRCC patients. (A–E) 
Overall survival was evaluated 
in 35 metastatic chromophobe 
renal cell carcinoma (M-chRCC) 
patients based on TP53 (A) and 
PTEN (B) mutational status, 
imbalanced chromosome 
duplication (ICD) status (C), and 
sarcomatoid status (D) in the 
primary tumors, but also on the 
presence or absence of TP53 
mutation, PTEN mutation, or 
ICD (E). Kaplan-Meier method 
and the log-rank test were used 
to compare the overall survival 
between groups. Cox regression 
estimated the hazard ratios 
(HRs).
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There are shared molecular features between 
the ICD (+) cases of  chRCC in the TCGA-KICH 
cohort and the whole-genome duplication (+) cases 
of  ccRCC in the TCGA-KIRC cohort. Recent 
pan-cancer analysis of somatic copy number 
alterations demonstrated that a majority 
of cancer is nearly diploid, whole-genome 
duplication (WGD) occurs in 37% of cancers 
with a ~3.31 mean ploidy, and recurrent 
whole-chromosome loss is uncommon (26). 
Of note, WGD within the TCGA kidney 
renal clear cell carcinoma (TCGA-KIRC) 
cohort was 20%. As ICD and WGD both 
manifest with gains of many chromosomes, 
we determined their molecular relationship 
in RCC and identified striking transcriptomic 
similarities between the ICD (+) chRCC 
and the WGD (+) ccRCC. Among the 451 
upregulated genes in ICD (+) chRCC, 401 
(89%) were up in WGD (+) ccRCC compared 
with WGD (–) ccRCC, and among the 525 
downregulated genes in ICD (+) chRCC, 415 
(79%) were down (χ2 test, P < 1 × 10–30) (Figure 
6A). Hence, the molecular signature conferred 
by ICD in chRCC is highly concordant with 
that by WGD in ccRCC, implying a shared 
pathway convergent evolution between 2 
kidney cancer subtypes (28, 36).
WGD (+) ccRCC patients in the TCGA-
KIRC cohort exhibit inferior survival outcome. 
Our study thus far identified ICD as a 
candidate high-risk genomic feature of  
chRCC (Figure 2A and Supplemental Figure 
4) and recognized the marked similarity in 
transcriptomes between chRCC with ICD 
and ccRCC with WGD (Figure 6A). We 
next investigated whether the presence of  
Figure 6. Molecular features shared between 
the ICD of the TCGA-KICH chRCC cases and 
the WGD of the TCGA-KIRC ccRCC cases. (A) 
Transcriptomic analysis depicts differentially 
expressed genes in the TCGA-KICH (n = 66) and 
in the TCGA-KIRC cohort (n = 370) according to 
the imbalanced chromosome duplication (ICD) 
(KICH) or whole-genome duplication (WGD) status 
(in TCGA-KIRC based on Zack et al.; see ref. 26). 
Enriched pathways are specified. Mutation status 
of TP53 was also noted. (B) DNA methylation and 
differential expression of chr19q13 genes in the 
TCGA-KICH cohort with TP53 mutation status and 
ICD status of each sample denoted on the top. (C) 
Kaplan-Meier survival curves of the TCGA-KIRC 
cohort (n = 373) stratified based on the WGD 
status, WGD no (n = 298) and WGD yes (n = 75) 
(see Supplemental Table 7). P < 0.0001 by log-
rank test (Mantel-Cox).
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WGD in the primary tumors impacts the survival outcome of  ccRCC patients, which to our knowledge has 
not been interrogated. Kaplan-Meier survival curves of  the TCGA-KIRC cohort patients stratified based 
on the WGD status of  primary tumors showed a statistically significant inferior survival with WGD (+) 
ccRCC patients (P < 0.0001) (Figure 6C and Supplemental Table 7). Notably, WGD also negatively impacts 
the survival of  colorectal and adrenocortical cancer patients (37, 38). Here we demonstrated the shared 
transcription signature and inferior survival between ICD (+) chRCC and WGD (+) ccRCC, implicating 
ICD as a WGD variant. How and whether ICD/WGD actively participates in RCC cancer progression and 
impacts clinical outcome remain to be determined.
Discussion
The principal cause of  cancer death is distant metastasis, which entails diverse mechanisms and 
invokes distinct genes/pathways that could be either common to all cancers or relatively unique to 
individual cancer types. Alteration in chromosome number is a cardinal feature of  human cancer and 
could reflect underlying genome instability (39). However, as chromosomal loss could compromise 
cellular proliferation (22), we had long been intrigued by how chRCC, a tumor characterized by 
many whole-chromosome losses, can metastasize and kill patients. Due to its rarity, contemporary 
genomic reports on chRCC are limited to smaller cohorts that mainly consist of  nonmetastatic cases 
(5). Here, we investigated the genomic features underlying the metastatic progression of  chRCC 
through comparing genomics of  the primary tumors between M-chRCC patients and those who had 
not developed metastasis (ID-chRCC). A WGS cohort of  5 M-chRCC cases and an MSK-IMPACT 
cohort of  an additional 74 cases (33 M-chRCC, and 41 nonmetastatic ID-chRCC) were compiled in 
addition to the publically available TCGA-KICH cohort of  66 cases (12 M-chRCC and 54 nonmetastatic 
ID-chRCC). Upon genomic analysis of  the primary tumors from 144 chRCC patients (49 M-chRCC and 
95 nonmetastatic ID-chRCC), increased frequencies of  TP53 mutations, PTEN mutations, and ICD were 
noted in M-chRCC (55%, 27%, and 43%) compared with nonmetastatic ID-chRCC (25%, 7%, and 10%). 
Moreover, these 3 high-risk genomic events negatively impacted the survival outcome, lending clinical 
significance concerning these metastasis-enriched genomic features in chRCC.
Our study confirmed the nearly universal loss of  chRCC-7set chromosomes in the MRCA clone of  
all genomically examined ccRCC, which probably denotes a very early driver event in the pathogenesis 
of  chRCC, and determined an increasing incidence of  TP53 and PTEN mutations during the metastatic 
progression of  chRCC. Phylogenic studies of  paired primary-metastatic samples demonstrated that TP53 
mutations were detected in 82% of  M-chRCC samples, indicating that TP53 mutation is the second most 
favored genomic event. Interestingly, after the chRCC-7set–chromosomes loss and the TP53 mutation, ICD 
and PTEN mutation were the third most common genomic events and they appeared to occur in a mutually 
exclusive manner (Fisher, P = 0.0033) (Supplemental Figure 5), suggesting a functional convergence 
through PTEN mutation or ICD. As TP53 and PTEN are located at chRCC-7set chromosomes 17 and 10, 
heterozygous mutations in either gene would result in complete functional loss, which might explain the 
observed preferential mutations at these 2 tumor suppressor genes (TSGs) more than the other TSGs such 
as CDKN2A located at chromosome 9.
Although chRCC is relatively indolent, once metastasized the survival of  M-chRCC patients is as poor 
as metastatic ccRCC (13). Due to the rarity (~5% of  RCC) and the low (5%–10%) incidence of  eventual 
metastases, only limited clinical parameters such as tumor sizes and sarcomatoid changes were shown to 
affect clinical outcome (40), and no specific follow-up guideline has been developed for chRCC patients. 
Currently, nonmetastatic RCC patients of  all histological subtypes after surgery were followed according 
to contemporary guidelines that are generalized and formulated based on integrated prognostic algorithms 
developed for ccRCC (41, 42). Within the TCGA-KICH cohort, patients whose primary tumors exhibited 
none of  the 3 high-risk features, i.e., TP53 mutations, PTEN mutations, or ICD, had a 5-year OS of  97%, 
whereas those with any had a 5-year OS of  74%. Furthermore, within our M-chRCC case cohort, patients 
whose primary tumors exhibited none of  these features had an excellent 5-year OS of  100% and those with 
any had a dismal 5-year OS of  37%. Thus, TP53 mutation, PTEN mutation, and ICD might have prognostic 
value in chRCC. Likewise, BAP1, PBRM1, SETD2, and TP53 mutations in ccRCC (43–45), the CpG island 
methylator phenotype (CIMP) in pRCC (4), and the NF2 mutations in uRCC (8) are genomic features 
that have been shown to carry clinical significance in an RCC-subtype-specific manner. Thus far, all these 
genomic discoveries were made in retrospective studies utilizing archived tumor samples, which warrant 
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further validation. Once validated, they would be invaluable in the future construction of  individualized 
follow-up plans and treatment algorithms for kidney cancer patients.
Methods
Tumor samples. A total of  90 chRCC tumor samples, 5 frozen and 85 FFPE tumor samples along with their 
matched germline blood or uninvolved tissue, representing 79 patients, were collected under respective 
IRB protocols to undergo NGS. Forty-nine tumor samples, including 37 primary and 12 metastatic tumors 
from 38 patients with advanced chRCC (M-chRCC), were collected at the Memorial Sloan Kettering 
Cancer Center (24 cases), Mayo Clinic (7 cases), and UCLA (7 cases). The remaining 41 primary tumors 
were derived from 41 nonmetastatic chRCC patients who presented with localized disease at the time 
of  sampling and the last documented follow-up. Each slide was re-reviewed by a single genitourinary 
pathologist (S.K.T.) to confirm histology of  chRCC and tumor content before microdissection. Equivocal 
lesions were excluded from further DNA extraction and preparation. Clinical features of  the exploratory 
cohort (n = 74) are summarized in Table 1 and Supplemental Table 1.
WGS. WGS of  fresh-frozen tumors and matched normal tissues from 5 M-chRCC cases (4 primary 
tumors, 1 metastasis) was performed by the New York Genome Center on an Illumina HiSeq 2500. Tumor 
samples were sequenced to mean haploid depth coverages of  87× and 91×, while normal samples were 
sequenced to 51× and 47×. More than 96% of  the genome was sequenced to at least 10× in all cases. 
Short-insert paired-end reads were aligned to the GRCh37 reference human genome with 1,000 genomes 
decoy contigs using BWA-mem (46). For further information on somatic mutation calling for substitutions, 
insertions, deletions, structural rearrangements, and copy number changes, please refer to the Supplemental 
Data section.
Custom target sequencing. Seventy-four primary tumor and 11 metastasis samples were analyzed using 
MSK-IMPACT, as previously described. This clinical sequencing assay is a hybridization capture-based 
NGS assay for targeted deep sequencing of  all exons and selected introns of  341 or 410 oncogenes, TSGs, 
and members of  pathways deemed actionable by targeted therapies (Supplemental Table 2). Unstained 
sections from paraffin-embedded tissue blocks were microdissected to ensure tumor purity. DNA was 
purified using the DNeasy Blood & Tissue Kit (Qiagen, 69504). Genomic DNA from tumor and patient-
matched normal samples underwent library preparation using the KAPA HTP protocol (Kapa Biosystems) 
and the Biomek FX system (Beckman Coulter). Custom DNA probes targeting exons and selected 
introns were synthesized using the NimbleGen SeqCap EZ library custom oligo system and are listed in 
Supplemental Table 2. Details on massive parallel sequencing and alignment of  postcapture libraries on the 
Illumina HiSeq 2500 and sequence data analysis are described in the Supplemental Methods section. The 
impact-targeted DNA sequencing data is available for public access at cBioPortal (http://cbioportal.mskcc.
org/study?id=chrcc_mskcc_2015#summary) (47). Any other data that are included in the article and its 
supplemental material will be available from the authors upon request.
FACETS for somatic copy number analysis. FACETS is an ASCN analysis tool and open-source software 
with a broad application to WGS, WES, as well as targeted-panel sequencing platforms developed by 
V.E.S. (33). We employed FACETS for WES data from 66 primary tumor samples from the TCGA-KICH 
project and for 73 primary tumor and 12 metastases samples profiled by the MSK-IMPACT platform. In 
both sample types analyzed, FACETS enhanced the sensitivity to facilitate the identification of  aneuploid 
tumors by joint modeling of  total and allele-specific patterns. In addition, FACETS enabled the systematic 
identification of  clonal and subclonal copy number events through a cellular fraction feature in the model. 
Moreover, reliable interpretation of  NGS-based gene copy number calls in clinical sequencing panels was 
possible due to accurate, purity-, ploidy-, and clonal heterogeneity-adjusted, integer copy number calls 
delivered by FACETS. For detailed information please refer to the related publication (33).
In brief, the key steps for joint-segmentation and ASCN analysis were as follows. (a) Generation of  total 
copy number log-ratio (logR): Sequence read count information was first parsed from paired tumor-normal 
BAM files, with a normalizing constant being calculated for each tumor-normal to correct for total library 
size. To reduce hypersegmentation in SNP-dense regions of  the genome, subsampling within a 150- to 250-
bp interval was applied. logR was then computed from the total read count in the tumor versus normal for 
all SNPs that had a minimum depth of  coverage in the normal. (b) Generation of  allelic copy number log 
odds-ratio (logOR): To avoid significant bias toward higher mapping rates for the reference allele compared 
with those for the variant allele at heterozygous loci, we used the logOR of  the variant-allele count in 
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tumor versus normal, which is an unbiased estimate of  allelic copy ratio. (c) Joint segmentation analysis: 
To identify regions of  the genome that have constant copy number using change-point detection methods, 
we employed a model distinct from the conventional method in which both logR and BAF are computed 
for heterozygous loci only. In fact, we extended the circular binary segmentation (CBS) algorithm (48) to a 
joint segmentation of  logR and logOR based on a bivariate Hotelling T2 statistic. After segmentation, we 
clustered the segments into groups of  the same underlying genotype to reduce the number of  latent copy 
number and cellular fraction states needed in subsequent modeling.
FACETS call of  integer copy number. To model both clonal and subclonal events, we obtained integer 
copy number (major and minor) and the associated cellular fraction estimates for each segment cluster by 
modeling the expected values of  logR and logOR given total (t), and each parental (m,p) copy as a function 
of  a cellular fraction (cf) parameter ϕ, using a combination of  parametric and nonparametric methods. This 
allowed us to model both clonal and subclonal events.
Call of  ICD. Based on the outputs of  FACETS, we manually analyzed the samples to assess ICD. We 
excluded all samples with purity estimation below 0.3 (tumor DNA content < 30%) and/or with high level 
of  noise due to purity issues in order to avoid confounders due to hypersegmentation. Excluded samples 
were called NA. The logR was compared to the logOR and the copy number output. If  copy number 
changes greater than 2 were computed for chromosomes with corresponding LOH, the estimates of  cancer 
cell fraction (CCF) for these specific regions were evaluated to assess reliability of  duplication. A finding of  
3 or more chromosomes duplicated in the genome of  1 sample was called ICD.
Affymetrix OncoScan. The performance of  our ASCN analysis method FACETS was validated with 2 
independent methods on selected samples. First we analyzed genome-wide DNA copy number alterations 
and allelic imbalances by SNP array using the Affymetrix OncoScan FFPE Assay in 17 samples (34). This 
is a molecular inversion probe technology for the identification of  copy number alterations and LOH. We 
used 80 ng of  genomic DNA for each sample. Processing of  samples was performed according to the manu-
facturer’s guidelines (Affymetrix). Assay data were analyzed by the combination of  OncoScan Console 
software (Affymetrix) and OncoScan Nexus Express software (BioDiscovery) using the Affymetrix TuScan 
algorithm. OncoScan SNP-array data were analyzed by the software couple,  OncoScan Console and 
Nexus Express, using the Affymetrix TuScan algorithm. All array data were also manually reviewed for 
subtle alterations not automatically called by the software. The total copy number and BAF plots generated 
by this platform allow overcoming the low resolution of  the analysis originated using MSK-IMPACT data 
and confirm the copy number analysis by FACETS.
FISH. To further leverage our copy number findings from FACETS, FISH was performed on 14 
FFPE samples using probes targeting chromosome loci that are supposed to be informative for verifying 
copy number changes demonstrated by FACETS. FISH probes employed in this study included a 3-color 
in-house probe for 1q23 (NTRK1 locus), 2p23 (ALK locus), and pericentromere of  chromosome 4 (4p11 
locus), and a 2-color commercial probe purchased from Abbott Molecular for 4p16 (FGFR3 locus) and 
14q32 (IGH locus). Probe labeling, tissue processing, hybridization, posthybridization washing, and 
fluorescence detection were performed according to standard procedures. Slides were scanned using a 
Zeiss Axioplan 2i epifluorescence microscope equipped with a megapixel CCD camera (CV-M4+CL, 
JAI) controlled by Isis 5.5.9 imaging software (MetaSystems Group Inc.). The nontumor regions or 
normal cells (stromal cells and infiltrating lymphocytes) within tumors served as internal controls to 
assess quality of  hybridization. The entire section was scanned under an ×63 or ×100 objective to assess 
copy number and representative regions imaged through the depth of  the tissue. Signal enumeration 
was performed on the captured images and a minimum of  100 discrete nuclei analyzed. FISH analysis 
with these probes enabled us to conclusively confirm copy number changes detected by sequencing data 
in single cells from primary and metastatic tumors.
Reconstruction of  subclonal composition. To reconstruct the subclonal composition of  the analyzed 
tumors, we based our assumptions on previously published methods for subclonal reconstruction (49, 
50). Given the high coverage of  the MSK-IMPACT assay (432× for samples included in the analysis), 
we consider the subclonal reconstruction feasible. Segments of  copy number changes of  20-markers 
long or less were discarded. Segments with an insufficient number of  heterozygous SNPs and where 
FACETS results did not estimate minor copy number call were excluded. Alterations (somatic copy 
number and gene mutations) with CCF above 75% were considered clonal (100%), as previously 
described (51). Pairs of  copy number alterations or mutations with CCF within 10% of  each other 
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were considered to be in the same subclone with CCF equal to average value (there were no triplets of  
mutations within 20% range of  each other). Copy number alterations and mutations with CCF within 
5% were considered to be the same subclone.
We calculated CCF based on the formula, CCF = V(CR + 2[1 – R])/R, where V is the variant allele 
frequency of  the mutation, R is the tumor purity, and C is the local copy number. For mutations on the X 
chromosome in males, CCF = V/R. Multiple subclones with CCF less than 50% are consistent with more 
than 1 possible scenario: nested subclones (mutations in the same cells), shown in figure for simplicity, 
and parallel subclones (mutations in disjoint sets of  cells). Since the copy number estimates are based 
on a targeted-sequencing panel, complex copy number changes could not be estimated with sufficient 
precision. Therefore, specific chromosomes were excluded from the reconstruction, given complex copy 
number patterns estimated by FACETS in one of  the tumors: patient 1 (P-0002449), chromosome 11; 
patient 2 (JHkich60/P-0003003), chromosomes 5p, 8, 9p, 16p, 19q; patient 3 (JHkich59), chromosomes 1q, 
5, 9, 10q, 12p, 15, 17q, 22, 23; patient 4 (JHnccRCC004), chromosomes 5p, 21, 23; patient 5 (P-0002825), 
chromosomes 2q, 3, 4q, 6q, 16, 19p.
Statistics. To address the question, whether detected mutations in chRCC are associated with metastatic 
chromophobe disease, we analyzed a cohort of  99 patients, upon removal of  patients with missing clinical 
information or indeterminate clinical status. Of  these patients, the 64 TCGA patients (TCGA-KICH 
cohort) (52) with available clinical information served as a population-based sample of  controls, with 0 
samples missing ICD status. Thirty-five metastatic patients from Mayo, Memorial Sloan Kettering Cancer 
Center, and UCLA served as the sample of  cases (M-chRCC). Of  these patients, 9 are missing ICD status 
and were therefore excluded from any analysis of  this variable. OS was calculated from date of  diagnosis 
of  renal cancer to date of  death or last documented follow-up. The Kaplan-Meier method estimated OS 
probability and the log-rank test was used to compare OS between groups. Cox regression was used to 
estimated hazard ratios (HRs). A P value less than 0.05 was considered statistically significant.
Study approval. For the sequencing study of  all cases from Memorial Sloan Kettering Cancer Center, 
patients signed an informed consent (06-107 or 89-076) and the study was performed under a protocol 
reviewed and approved by the Memorial Sloan Kettering Cancer Center’s IRB under IRB protocol 
WA-0395-12. Data and samples collected from the Mayo Clinic and UCLA were exempted from IRB 
approval as all samples were anonymous and completely de-identified. 
Transcriptomic analysis of  chRCC. To compare ICD (+) and ICD (–) chRCC samples within the TCGA-
KICH (52) cohort, we analyzed the gene expression profiles by RNA sequencing in both groups stratified 
by our ICD calls based on FACETS analysis. Furthermore, we also analyzed WGD (+) and WGD (–) 
ccRCC samples from the TCGA-KIRC (53) cohort in the same fashion (26). FDRs corresponding to the 
differential genes were computed using a previously described method (54) and are listed in Supplemental 
Table 5. Of  the ICD differential genes at a significance level of  P less than 0.01, true positives should be 
represented on the order of  80%.
Pathway enrichment testing was by 1-sided Fisher’s exact test (P < 0.01 significance level), using 
SigTerms software tool (55). Significance of  overlap between ICD and WGD for upregulated genes was P 
less than 0.0001 (169 genes intersecting), and for downregulated genes P less than 0.0001.
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